-1200x645-800x430.jpg)
- Hudson Institute receives $1 million government grant
- Innovative project to treat widespread childbirth injuries
- Extension of Sofra oligonucleotides usage
Noxopharm (ASX:NOX) has welcomed the awarding of a $1 million medical research future fund grant to the Hudson Institute of Medical Research team for a project involving the company’s innovative Sofra platform.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
Hudson Institute is Noxopharm’s strategic partner in the development of the Sofra technology, and the MRFF is an Australian government research fund aiming to improve lives, build the economy and contribute to health system sustainability.
The grant is for a three-year project aiming to address the significant issue of birth injuries that lead to chronic and debilitating pelvic floor disorders (PFDs) in women.
According to industry research, approximately one in four women are affected by PFDs and there is currently no cure. The global PFD treatment market is currently worth US$2.8 billion and is expected to grow to around US$4.3 billion by 2032.
The Hudson Institute team will explore the use of Noxopharm’s Sofra oligonucleotides to treat birth injuries by incorporating them into a topical cream designed to reduce the inflammation associated with development of PFDs and enable the conditions for tissue regeneration.
Noxopharm CEO, Dr Olivier Laczka, said this novel idea for a cream that would be easy to use, scale up and distribute has never been explored before in maternal pelvic health and obstetrics care.
He said the project mirrors Noxopharm’s own development of SOF-SKNTM, which recently successfully completed a Phase I clinical trial. The Hudson Institute project demonstrates that using anti-inflammatory oligonucleotides in a skin cream could have applications across numerous skin-related diseases and conditions, each with potentially sizeable markets.
“Hudson Institute is at the forefront of inflammation-related research in Australia, and this is yet another example of their innovative approach to ongoing public health challenges,” Dr Laczka said.
“It also shows the versatility inherent in the Sofra platform, and how our technology can be used in a wide variety of circumstances to tackle inflammation.”
Developed from a breakthrough discovery in innate immunology, the Sofra technology platform represents a revolutionary approach to drug design by translating a new understanding of innate biology into targeted therapeutics that enable precision control of disease-relevant signalling.
Sofra is based on the use of synthetic nucleic acids, known as oligonucleotides, to mimic natural regulators of the body’s defence system.
The novel approach enables selective and modular tuning of immune sensors, reducing or stimulating their associated biological responses to mitigate a broad range of diseases and enhance RNA-based therapies and emerging therapeutic technologies.
NOX is up 9.41% to 9.3¢. Mkt cap $26.11M.
Join the discussion: See what HotCopper users are saying about Noxopharm and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.